BEAM

Beam Therapeutics Inc

24.27

Oct 22 • 1:12 PM ET -0.57 (-2.29%)

Healthcare Biotechnology USA Mid NASD

Peers: NTLA CRSP PRME EDIT WVE SCTX KRRO ARWR VRTX DTIL

| Held by: ARKE ARKK XBI VTI ARKG IWM VB VBK VXF IWO

Index	RUT
Market Cap	2.51B
Enterprise Value	1.60B
Income	-85.43M
Sales	156.03M
Book/sh	10.34
Cash/sh	11.16
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	511
IPO	Feb 06, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	16.07
P/B	2.35
P/C	2.17
P/FCF	-
EV/EBITDA	-
EV/Sales	10.26
Quick Ratio	14.57
Current Ratio	14.57
Debt/Eq	0.23
LT Debt/Eq	0.22
Option/Short	Yes / Yes

EPS (ttm)	-0.86
EPS next Y	-4.81
EPS next Q	-1.15
EPS this Y	-447.29%
EPS next Y	-8.40%
EPS next 5Y	-
EPS past 3/5Y	41.92% 28.04%
Sales past 3/5Y	31.88% 466.27%
EPS Y/Y TTM	81.95%
Sales Y/Y TTM	158.88%
EPS Q/Q	-17.25%
Sales Q/Q	-94.21%
Earnings	Aug 04 BMO
EPS/Sales Surpr.	-6.65% -97.01%

Insider Own	7.81%
Insider Trans	-4.75%
Inst Own	97.66%
Inst Trans	0.94%
ROA	-6.15%
ROE	-8.08%
ROIC	-6.57%
Gross Margin	85.74%
Oper. Margin	-242.27%
Profit Margin	-54.75%
SMA20	-1.34%
SMA50	-6.87%
SMA200	-14.21%
Trades

Shs Outstand	103.26M
Shs Float	95.23M
Short Float	28.93%
Short Ratio	15.35
Short Interest	27.55M
52W High	38.26 -36.57%
52W Low	20.23 19.97%
Volatility	5.29% 5.36%
ATR (14)	1.31
RSI (14)	45.93
Beta	2.26
Rel Volume	0.52
Avg Volume	1.80M
Volume	552,143

Perf Week	-1.86%
Perf Month	-0.41%
Perf Quarter	-3.31%
Perf Half Y	-19.53%
Perf YTD	-12.45%
Perf Year	-12.32%
Perf 3Y	37.20%
Perf 5Y	-74.11%
Perf 10Y	-
Recom	1.25
Target Price	51.07
Prev Close	24.84
Price	24.27
Change %	-2.29%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-20-26	Initiated	Canaccord Genuity	Buy	$74
Oct-09-25	Initiated	Jefferies	Buy	$41
Mar-28-25	Upgrade	BofA Securities	Neutral → Buy	$42
Mar-10-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform	$40
Jan-29-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-06-24	Upgrade	Leerink Partners	Market Perform → Outperform	$27 → $39
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jul-23-24	Initiated	H.C. Wainwright	Buy	$80
Jan-29-24	Upgrade	JP Morgan	Neutral → Overweight	$38 → $40
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral	$35
Dec-08-23	Downgrade	Jefferies	Buy → Hold	$75 → $30
Oct-20-23	Downgrade	Leerink Partners	Outperform → Market Perform	$75 → $20
Oct-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Mar-21-23	Initiated	Bernstein	Mkt Perform	$37
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$62
Dec-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$61 → $66
Dec-13-22	Initiated	Citigroup	Buy	$62
Jun-17-22	Initiated	BMO Capital Markets	Market Perform	$41
Apr-28-22	Initiated	Credit Suisse	Neutral	$62
Jan-05-22	Initiated	Guggenheim	Buy	$130

Show Previous Ratings

Oct-13-26 07:00AM	Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress (GlobeNewswire)
Sep-29-26 02:34PM	Beam sues 2 biotechs, alleging theft of base editing trade secrets (BioPharma Dive)
Sep-28-26 03:11PM	Cathie Wood Makes $64 Million Bet on Two Stocks (GuruFocus.com)
Sep-24-26 08:46AM	Anthropic AI Discovery Gene-Editing Stocks Falling (GuruFocus.com)
Sep-22-26 07:10AM	Beyond Meta, Cathie Woods ARKG Loads Up On These 4 Biotech Names (Stocktwits)
06:00AM	Loading…
Sep-08-26 06:00AM	Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 (GlobeNewswire) -9.54%
Sep-01-26 07:00AM	Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer (GlobeNewswire)
Aug-31-26 07:00AM	Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences (GlobeNewswire)
Aug-04-26 07:00AM	Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire) +9.42%
Jul-27-26 04:08PM	Scribe's Genetic Editing Aims to Prevent Heart Attacks (Barrons.com)
Jul-23-26 07:00AM	Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 (GlobeNewswire)
Jul-08-26 04:10PM	Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle (Investor's Business Daily)
12:47PM	PRME Surges 15% After Winning Arbitration Against Beam Clears Path To Human Trials For Its Gene-Editing Drug (Stocktwits)
05:07AM	Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal (BioPharma Dive)
Jun-18-26 07:00AM	Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration (GlobeNewswire) +5.11%
04:00PM	Loading…
May-18-26 04:00PM	Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference (GlobeNewswire)
May-13-26 11:49AM	Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 (PR Newswire)
07:00AM	Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-12-26 09:30AM	Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel's Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026 (GlobeNewswire)
May-07-26 07:00AM	Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates (GlobeNewswire)
Apr-01-26 05:12PM	Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine (GlobeNewswire)
Mar-25-26 07:00AM	Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development (GlobeNewswire)
Mar-03-26 04:30AM	Apellis Pharmaceuticals Details SYFOVRE, EMPAVELI Growth Plans and FcRn Gene-Editing Push at TD Cowen Conf. (MarketBeat) -5.12%
Feb-28-26 02:21AM	RBC Capital Maintains a Sector Perform Rating on Beam Therapeutics (BEAM), Here's Why (Insider Monkey)
Feb-25-26 11:03AM	BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks) -8.30%
Feb-24-26 08:03PM	Beam Therapeutics Inc. Q4 2025 Earnings Call Summary (Moby) +13.98%
02:07PM	What's Going On With Beam Therapeutics Stock? (Benzinga)
02:01PM	Beam Therapeutics Inc (BEAM) Q4 2025 Earnings Call Highlights: Strategic Financing and ... (GuruFocus.com)
10:44AM	Beam Therapeutics Q4 Earnings Call Highlights (MarketBeat)
10:44AM	Apellis Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
08:50AM	Loading…
08:50AM	Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
07:01AM	Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) (GlobeNewswire)
07:00AM	Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street (GlobeNewswire)
Feb-23-26 04:00PM	Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program (GlobeNewswire)
Feb-20-26 10:48AM	Genomics Stocks That Deserve a Place in Your Portfolio in 2026 (Zacks)
09:39AM	Walmart downgraded, Etsy upgraded: Wall Street's top analyst calls (The Fly)
Feb-18-26 07:39PM	Analyst Bullish on Beam Therapeutics (BEAM) Over Drug Program Trajectory (Insider Monkey)
Feb-17-26 04:58PM	Cathie Wood Buys COIN, HOOD (GuruFocus.com)
Feb-16-26 12:23PM	Here is Why Beam Therapeutics (BEAM) Appears so Attractive (Insider Monkey)
05:42AM	Cathie Wood Buys COIN After 16% Jump (GuruFocus.com)
Feb-15-26 11:33PM	Cathie Wood buys $46 million of tumbling tech stock (TheStreet)
08:41AM	H.C. Wainwright Reiterated Buy on Beam Therapeutics (BEAM) After BEAM-302 FDA Expedited Approval (Insider Monkey)
Jan-29-26 07:17AM	Bernstein Maintains an Outperform Rating on Beam Therapeutics Inc. (BEAM) (Insider Monkey)
Jan-13-26 01:00PM	BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises (Zacks)
Jan-12-26 04:15PM	Beam Soars 22% As FDA Signs Off On Its Ambitious Gene-Editing Plan (Investor's Business Daily) +22.29%
03:37PM	Apellis Pharmaceuticals Details Syfovre Growth, Prefilled Syringe Filing at JPM Healthcare Conference (MarketBeat)
01:39PM	Beam Therapeutics Stock Surges: What's Driving The Sudden Jump? (Benzinga)
12:54PM	Beam Soars Nearly 30% As FDA Signs Off On Its Ambitious Gene-Editing Plan (Investor's Business Daily)
06:24AM	AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations (BioPharma Dive)
Jan-11-26 05:00PM	Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition (GlobeNewswire)
Jan-06-26 07:06AM	Three Genomics Stocks Worth Tracking This Year (Zacks) +5.59%
Jan-05-26 12:23PM	ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure (GuruFocus.com)
Dec-31-25 09:32AM	Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry? (Zacks)
06:26AM	Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab (GuruFocus.com)
Dec-30-25 11:46PM	Beam Therapeutics Inc. (BEAM) Reports Updated Data From BEACON Phase 1/2 trial Of Ristoglogene (Insider Monkey)
07:33AM	Do You Think Beam Therapeutics (BEAM) is an Undervalued Stock? (Insider Monkey)
Dec-29-25 12:51PM	TSLA: Cathie Wood Dumps $30 Million Worth Tesla Stock (GuruFocus.com)
Dec-22-25 06:50AM	BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy (Insider Monkey) +5.08%
Dec-18-25 04:01PM	Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-25 11:30AM	Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound? (Zacks)
Dec-09-25 11:57AM	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions (PR Newswire)
Dec-06-25 08:00AM	Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-04-25 11:30AM	Why Is Beam Therapeutics (BEAM) Up 15.9% Since Last Earnings Report? (Zacks) +8.12%
Nov-28-25 09:59AM	Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry? (Zacks)
Nov-27-25 08:15AM	BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential? (Zacks)
Nov-21-25 10:19AM	NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks) +7.82%
Nov-14-25 08:58AM	Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks? (Zacks)
Nov-12-25 07:31AM	Cathie Wood Dumps $2.4 Million Worth Of Tesla Shares, Doubles Down On These AI Stocks (Benzinga)
07:00AM	Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference (GlobeNewswire)
Nov-10-25 08:16PM	Clear Street Raises PT on Beam Therapeutics (BEAM) to $37 Following Q3 Results (Insider Monkey)
Nov-05-25 10:48AM	Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y (Zacks)
10:41AM	Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up (Zacks)
10:30AM	Novo Nordisk Q3 Earnings & Revenues Miss, GLP-1 Drugs Face US Hurdles (Zacks)
Nov-04-25 03:37PM	Cathie Wood unloads $7.69 million in top AI stock (TheStreet) -6.23%
03:37PM	Cathie Wood sells another $7.69 million in leading AI stock (TheStreet)
11:43AM	ZTS Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down (Zacks)
09:54AM	Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
08:35AM	Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates (GlobeNewswire)
Nov-03-25 10:11AM	Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings? (Zacks)
09:00AM	Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-25 01:45PM	Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates (Zacks) +5.08%
01:44PM	AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues (Zacks)
10:37AM	ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales (Zacks)
Oct-30-25 12:08PM	Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down (Zacks)
Oct-29-25 11:24AM	United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss Mark (Zacks) -6.28%
11:18AM	RGEN'S Q3 Earnings Beat Estimates, Revenues Surge Y/Y, Stock Down (Zacks)
09:55AM	Beam Therapeutics (BEAM) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Oct-28-25 11:44AM	Beam Therapeutics Inc. (BEAM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-20-25 09:55AM	Beam Therapeutics Inc. (BEAM)'s Technical Outlook is Bright After Key Golden Cross (Zacks) +17.86%
09:25AM	Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition? (Zacks)
Oct-17-25 09:55AM	Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 76.15%: Read This Before Placing a Bet (Zacks)
09:40AM	Is Beam Therapeutics (BEAM) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-11-25 10:02AM	Jim Cramer on Beam Therapeutics: "That's the Speculative Bottom There" (Insider Monkey)
Oct-08-25 12:57AM	What Does Wall Street Think About Beam Therapeutics (BEAM)? (Insider Monkey) +7.44%
Oct-07-25 08:28PM	Lightning Round: Shopify is going much higher, says Jim Cramer (CNBC TV)
Sep-18-25 11:35AM	3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025 (Zacks) +11.80%
Sep-17-25 02:18PM	H.C. Wainwright Maintains Buy on Beam (BEAM), $80 Target on Pipeline Momentum (Insider Monkey)
Sep-12-25 11:30AM	Why Is Allogene Therapeutics (ALLO) Up 9.4% Since Last Earnings Report? (Zacks)
Aug-29-25 10:22AM	Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy? (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Evans John M.	CEO	Oct 15 '26	Option Exercise	1.03	25,000	25,750	1,072,205	Oct 16 08:09 PM
Evans John M.	CEO	Oct 16 '26	Option Exercise	1.03	25,000	25,750	1,072,205	Oct 16 08:09 PM
Evans John M.	CEO	Oct 16 '26	Sale	23.98	25,000	599,595	1,047,205	Oct 16 08:09 PM
Evans John M.	CEO	Oct 15 '26	Sale	23.57	25,000	589,150	1,047,205	Oct 16 08:09 PM
JOHN M EVANS	Officer	Oct 16 '26	Proposed Sale	23.98	25,000	599,595		Oct 16 04:12 PM
JOHN M EVANS	Officer	Oct 15 '26	Proposed Sale	23.57	25,000	589,150		Oct 15 04:23 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Oct 01 '26	Sale	24.41	187	4,565	50,984	Oct 02 04:05 PM
Simon Amy	Chief Medical Officer	Jul 27 '26	Sale	25.74	16,667	429,037	85,696	Jul 29 04:05 PM
AMY SIMON	Officer	Jul 27 '26	Proposed Sale	25.74	16,677	429,294		Jul 27 04:04 PM
Simon Amy	Chief Medical Officer	Jun 30 '26	Sale	34.73	373	12,954	102,363	Jul 02 04:05 PM
Evans John M.	CEO	Jun 30 '26	Option Exercise	1.03	25,000	25,750	1,072,205	Jul 01 04:05 PM
Evans John M.	CEO	Jun 29 '26	Option Exercise	0.76	25,000	19,031	1,072,205	Jul 01 04:05 PM
Evans John M.	CEO	Jun 29 '26	Sale	35.49	25,000	887,352	1,047,205	Jul 01 04:05 PM
Evans John M.	CEO	Jun 30 '26	Sale	34.31	25,000	857,685	1,047,205	Jul 01 04:05 PM
JOHN M EVANS	Officer	Jun 30 '26	Proposed Sale	34.31	25,000	857,685		Jun 30 04:19 PM
JOHN M EVANS	Officer	Jun 29 '26	Proposed Sale	35.49	25,000	887,352		Jun 29 04:14 PM
FMR LLC	See Remark 1	Jun 26 '26	Sale	35.26	251,488	8,867,467	854,583	Jun 29 02:17 PM
FMR LLC	See Remark 1	Jun 25 '26	Sale	35.12	33,372	1,172,025	1,106,071	Jun 29 02:17 PM
Ciaramella Giuseppe	President	Jun 17 '26	Option Exercise	0.96	35,505	34,228	253,911	Jun 22 04:05 PM
CAROLE HO	Director	Apr 14 '26	Proposed Sale	30.73	87,784	2,698,015		Apr 14 04:28 PM
Evans John M.	CEO	Apr 01 '26	Sale	24.58	30,078	739,317	1,047,205	Apr 06 05:48 PM
Simon Amy	Chief Medical Officer	Apr 01 '26	Sale	24.58	6,700	164,686	102,735	Apr 06 05:44 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Apr 01 '26	Sale	24.58	3,242	79,688	51,171	Apr 06 05:39 PM
Bellon Christine	Chief Legal Officer	Apr 01 '26	Sale	24.58	5,956	146,398	109,711	Apr 06 05:39 PM
Ciaramella Giuseppe	President	Apr 01 '26	Sale	24.58	11,810	290,290	218,406	Apr 06 05:34 PM
Evans John M.	CEO	Mar 30 '26	Option Exercise	0.67	25,000	16,750	1,011,667	Apr 01 06:32 PM
Evans John M.	CEO	Mar 31 '26	Option Exercise	0.67	25,000	16,750	1,011,667	Apr 01 06:32 PM
Evans John M.	CEO	Mar 31 '26	Sale	22.76	25,000	569,085	986,667	Apr 01 06:32 PM
Evans John M.	CEO	Mar 30 '26	Sale	22.37	25,000	559,230	986,667	Apr 01 06:32 PM
CHRISTINE BELLON	Officer	Apr 02 '26	Proposed Sale	21.90	20,000	438,000		Mar 31 04:33 PM
GIUSEPPE CIARAMELLA	Officer	Apr 02 '26	Proposed Sale	21.90	26,250	574,875		Mar 31 04:29 PM
AMY SIMON	Officer	Apr 02 '26	Proposed Sale	21.90	20,000	438,000		Mar 31 04:22 PM
JOHN M. EVANS	Officer	Apr 02 '26	Proposed Sale	21.90	66,874	1,464,541		Mar 31 04:19 PM
JOHN M EVANS	Officer	Mar 31 '26	Proposed Sale	22.76	25,000	569,085		Mar 31 04:16 PM
JOHN M EVANS	Officer	Mar 30 '26	Proposed Sale	22.37	25,000	559,230		Mar 30 05:28 PM
Ciaramella Giuseppe	President	Feb 24 '26	Option Exercise	17.00	35,000	595,000	225,216	Feb 26 04:05 PM
Ciaramella Giuseppe	President	Feb 24 '26	Sale	32.00	35,000	1,120,042	190,216	Feb 26 04:05 PM
GIUSEPPE CIARAMELLA	Officer	Feb 24 '26	Proposed Sale	32.00	35,000	1,120,042		Feb 24 04:15 PM
Evans John M.	CEO	Jan 29 '26	Option Exercise	0.67	25,000	16,750	1,011,667	Feb 02 04:05 PM
Evans John M.	CEO	Jan 30 '26	Option Exercise	0.67	25,000	16,750	1,011,667	Feb 02 04:05 PM
Evans John M.	CEO	Jan 29 '26	Sale	29.38	25,000	734,582	986,667	Feb 02 04:05 PM
Evans John M.	CEO	Jan 30 '26	Sale	28.36	25,000	708,946	986,667	Feb 02 04:05 PM
JOHN M EVANS	Officer	Jan 30 '26	Proposed Sale	28.36	25,000	708,948		Jan 30 04:04 PM
JOHN M EVANS	Officer	Jan 29 '26	Proposed Sale	29.38	25,000	734,582		Jan 29 04:01 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Jan 22 '26	Sale	35.00	6,198	216,933	34,813	Jan 26 04:05 PM
Bellon Christine	Chief Legal Officer	Jan 22 '26	Sale	34.00	1,371	46,614	95,667	Jan 26 04:05 PM
CHRISTINE BELLON	Officer	Jan 22 '26	Proposed Sale	34.00	1,371	46,614		Jan 22 04:03 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Jan 20 '26	Sale	30.12	3,034	91,384	41,011	Jan 21 04:05 PM
Bellon Christine	Chief Legal Officer	Jan 15 '26	Sale	34.61	18,629	644,832	97,038	Jan 20 04:05 PM
CHRISTINE BELLON	Officer	Jan 15 '26	Proposed Sale	34.61	18,629	644,831		Jan 15 06:00 PM
Emany Sravan Kumar	Chief Financial Officer	Dec 31 '25	Sale	27.10	6,294	170,567	73,706	Jan 05 04:16 PM
Bellon Christine	Chief Legal Officer	Dec 31 '25	Sale	27.10	1,254	33,983	115,667	Jan 05 04:12 PM
FMR LLC	See Remark 1	Oct 27 '25	Sale	26.68	459	12,246	14	Oct 29 01:13 PM

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

CEO & DirectorMr. John M. Evans M.B.A.

PresidentDr. Giuseppe Ciaramella Ph.D.

Chief Financial OfficerMr. Sravan Kumar Emany

Ph.D.Dr. Christine P. Bellon J.D.

Chief Medical OfficerDr. Amy Simon M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BEAM

Beam Therapeutics Inc

Upgrade your Finviz experience